Allergan takes Linzess on a run with differentiation push

Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, or is this an abdominal pain drug that improves constipation?" chief commercial officer Tom McCourt first asked company R&D chief Mark Currie. And because it was the latter, Ironwood and partner Allergan ($AGN) now stand apart from OTC offerings, a position that helped them grow U.S. sales to $454.8 million last year. More from FiercePharmaMarketing